search
Back to results

KAVIAR Study - Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures

Primary Purpose

Vertebral Body Compression Fractures

Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Vertebroplasty
Kyphoplasty
Sponsored by
Medtronic Spine LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Vertebral Body Compression Fractures focused on measuring Kyphoplasty, Vertebroplasty, Balloon Kyphoplasty, Inflatable Bone Tamp, Spine, Back Pain, Vertebral Compression Fracture, Vertebral Body Compression Fracture

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria All subjects must meet all of the following criteria to be enrolled into the study: Age > 21 1 to 3 target VCFs meeting the following criteria: Fracture due to diagnosed or presumed underlying primary or secondary osteoporosis All target VCFs are between T5 and L5 All target VCFs to be treated show either: i. Height change: An acute (< 6 month) change in VB height or morphology from a previous x-ray, CT or MRI, with height loss at the anterior, middle or posterior portion of the VB consistent with a worsening of 1 or more grades by the Genant criteria (17), OR ii. Positive MRI or bone scan: VB shows hyperintense signal on STIR sequence MRI or target VB is positive on radionuclide bone scan All VCFs to be treated have fracture age (time from pain onset to evaluation by the Investigator) of 6 months or less Back pain correlating with the location of at least one VCF Treatment of all target VCFs is technically feasible by and clinically appropriate for BOTH vertebroplasty and balloon kyphoplasty. (Team approach only: Both the vertebroplasty and balloon kyphoplasty physician have reviewed radiographic studies and agree to this prior to enrolling the subject in the study.) Pre-treatment back pain by numerical rating scale (NRS) score > 4 (0-10 scale) Pre-treatment Oswestry Disability Index >20 (0 - 100 scale) Subject states availability for all study visits Subject is able to understand the risks and benefits of participating in the study and is willing to provide written informed consent Subject has mental capacity to comply with the protocol requirements for 2-year duration of study Exclusion Criteria Subjects who meet any of the following conditions may not be enrolled into the study: VB morphology or configuration is such that either balloon kyphoplasty OR vertebroplasty is not technically feasible for the targeted VCFs Fracture due to high-energy trauma Suspected OR proven cancer inside index vertebral body. Note that patients with chemotherapy-related osteoporosis may be included. Disabling back pain due to causes other than acute fracture (e.g., sacroiliac fracture, symptomatic degenerative disc disease, lumbar spinal stenosis) Any painful VCF with fracture age > 6 months Any objective evidence of neurologic compromise at baseline Previous balloon kyphoplasty or vertebroplasty for any VCF Spine stabilization beyond balloon kyphoplasty or vertebroplasty required for targeted VCFs Significant clinical comorbidity that may potentially interfere with long-term data collection or follow-up (e.g., dementia, severe comorbid illness) Pre-existing conditions contrary to either balloon kyphoplasty or vertebroplasty, such as: Irreversible coagulopathy or bleeding disorder. Note regarding reversible coagulopathies: Subjects on coumadin or other anticoagulants may participate. Investigators should follow routine practices for perioperative discontinuation and re-initiation of anticoagulants. Allergy to any device materials (e.g., bone cement) for balloon kyphoplasty or vertebroplasty. Note that in subjects with allergy to iodine-based contrast, other non-iodine contrast solutions may be used. Any evidence of VB or systemic infection Pregnant or child-bearing potential

Sites / Locations

  • Scottsdale Medical Imaging, Ltd
  • Minimally Invasive Surgical Solutions
  • Torrance Memorial Medical Center
  • Western Slope Study Group
  • The Center for Spinal Disorders
  • Radiology Associates of Atlanta
  • Ochsner Medical Center
  • William Beaumont Hospital
  • Saint Luke's Hospital of Kansas City
  • Northwest Research & Educational Institute
  • Renown Regional Medical Center
  • University Orthopedics
  • Atrium Medical Center
  • The Toledo Hospital
  • Clinical Radiology of Oklahoma
  • The Center for Orthopedic and Neurosurgical Care and Research (The Center)
  • Reading Hospital
  • The Methodist Hospital Research Institute
  • Scott & White Memorial Hospital
  • Intermountain Medical Center
  • Utah Valley Regional Medical Center
  • Carilion Roanoke Memorial Hospital
  • St. Mary's Hospital
  • Aurora Burlington Memorial Hospital
  • Aurora St. Luke's Medical Center
  • Royal Victoria Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Kyphoplasty

Vertebroplasty

Arm Description

Outcomes

Primary Outcome Measures

Percent of Subjects With One or More Subsequent Radiographic Fractures at 12 Months
Percent of Subjects With One or More Subsequent Radiographic Fractures 24 Months

Secondary Outcome Measures

Back Pain
Back pain was assessed on a 10-point Numerical Rating Scale (NRS) from 0 (no pain) to 10 (worst possible pain).
Back Function-Oswestry Disability Index
The Oswestry Disability Index (ODI) Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).
Quality of Life by SF-36
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results are summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS and MCS is between 0 and 100, with higher scores denoting better quality of life.
Quality of Life -- EQ5D Index
EQ-5D index scores range from 0 to 1.0 on a scale where 0 = death and 1.0 = perfect health.
Rate of Serious Adverse Events at 30 Days
Rate of serious adverse events is presented as the percentage of the participants who reported serious adverse events within 30 days after initial treatment. For this study, serious adverse events (SAEs) included death, serious deterioration in health, life threatening injury/illness, hospitalization or prolonged hospitalization, or resulted in medical or surgical intervention.
Rate of Procedure/Device Related or Possibly Related Serious Adverse Events at 30 Days
Rate of Procedure/Device related or possibly related serious adverse events is presented as the percentage of the participants who reported Procedure/Device related or possibly related serious adverse events within 30 days after initial treatment.
Change in Anterior Vertebral Body Height
Change in Middle Vertebral Body Height
Change in Posterior Vertebral Body Height
Change in Vertebral Body Kyphosis Angle
The vertebral kyphosis angle was defined as the angle formed by lines drawn parallel to the superior and inferior endplates of the treated fractured vertebral body.
Change in Vertebral Body Local Cobb Angle (LCA)
The vertebral body local Cobb angle is a measurement of the 3-level functional unit consisting of the treated fractured vertebral body and the nearest adjacent vertebrae and is defined as the angle formed by lines drawn parallel to the superior endplate of the cranial adjacent vertebral body and the inferior endplate of the adjacent caudal vertebral body.
Change in Global Sagittal Balance.
Change in global sagittal balance as measured by sagittal vertical axis.
VCF-related Health Care Utilization
Health care utilization assessments conducted by monthly phone call to participating patients.

Full Information

First Posted
May 5, 2006
Last Updated
December 6, 2017
Sponsor
Medtronic Spine LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00323609
Brief Title
KAVIAR Study - Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures
Official Title
A Multicenter, Randomized, Prospective Clinical Trial to Compare the Short- and Long-term Safety and Effectiveness of Balloon Kyphoplasty to Vertebroplasty in the Treatment of Painful, Acute Osteoporosis-related Vertebral Body Compression Fractures (VCFs).
Study Type
Interventional

2. Study Status

Record Verification Date
June 2012
Overall Recruitment Status
Terminated
Why Stopped
Due to high number of patients terminating study early, low patient enrollment and difficulty in patient/investigator willingness for randomization
Study Start Date
August 2006 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Spine LLC

4. Oversight

5. Study Description

Brief Summary
Patients with osteoporotic vertebral body compression fractures will be randomly assigned to treatment with balloon kyphoplasty or vertebroplasty. Over 2 years of follow-up, back pain, back function, quality of life, adverse events, subsequent fractures and cumulative healthcare costs will be compared.
Detailed Description
Medtronic Spine LLC is sponsoring the KAVIAR study, a randomized clinical trial comparing balloon kyphoplasty to vertebroplasty for the treatment of osteoporotic vertebral body compression fractures (VCFs). Up to 1,234 subjects at up to 75 study centers with one to three VCFs and VB morphologies suitable for both balloon kyphoplasty and vertebroplasty will be randomly assigned to receive one or the other procedure. Study visits will occur at baseline, 30 days postoperatively, and at 3, 12 and 24 months postoperatively. At all visits, adverse events, back pain, back function and quality of life will be assessed. In addition, a 7-day phone call will be conducted, which will include assessment of back pain, narcotic use and adverse events. At baseline, pre-discharge, 3-, 12- and 24-month visits, lateral spine x-rays will be taken. The primary endpoint will be the proportion of patients with one or more subsequent fractures at 12 and 24 months, detected radiographically as determined by a core radiology laboratory. Secondary clinical endpoints include changes from baseline in back pain, back function and quality of life, and adverse events. Secondary radiographic comparisons include the restoration and maintenance of VB height and angulation, and sagittal vertical axis, a measure of global sagittal balance. A postoperative CT scan will be evaluated to detect cement extravasation and to examine the relationship between cement distribution and clinical outcomes. Another important feature of the study is a detailed healthcare utilization data assessment. Combined with a costing methodology based on Medicare cost data and other sources, cumulative two-year healthcare costs related to VCF will be estimated. Combined with quality of life measurements, the cost analysis will allow a calculation of the relative cost-effectiveness of balloon kyphoplasty and vertebroplasty. Sample size is based on the primary endpoint, the proportion with subsequent fractures at 12 and 24 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vertebral Body Compression Fractures
Keywords
Kyphoplasty, Vertebroplasty, Balloon Kyphoplasty, Inflatable Bone Tamp, Spine, Back Pain, Vertebral Compression Fracture, Vertebral Body Compression Fracture

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
404 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Kyphoplasty
Arm Type
Active Comparator
Arm Title
Vertebroplasty
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Vertebroplasty
Intervention Description
Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
Intervention Type
Procedure
Intervention Name(s)
Kyphoplasty
Intervention Description
Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
Primary Outcome Measure Information:
Title
Percent of Subjects With One or More Subsequent Radiographic Fractures at 12 Months
Time Frame
12 months
Title
Percent of Subjects With One or More Subsequent Radiographic Fractures 24 Months
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Back Pain
Description
Back pain was assessed on a 10-point Numerical Rating Scale (NRS) from 0 (no pain) to 10 (worst possible pain).
Time Frame
7 days, 30 days, 3 months, 12 months, 24 months post-operation
Title
Back Function-Oswestry Disability Index
Description
The Oswestry Disability Index (ODI) Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).
Time Frame
30 days, 3 months, 12 months, 24 months post-operation
Title
Quality of Life by SF-36
Description
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results are summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS and MCS is between 0 and 100, with higher scores denoting better quality of life.
Time Frame
30 days, 3 months, 12 months, 24 months post-operation
Title
Quality of Life -- EQ5D Index
Description
EQ-5D index scores range from 0 to 1.0 on a scale where 0 = death and 1.0 = perfect health.
Time Frame
30 days, 3 months, 12 months, 24 months post-operation
Title
Rate of Serious Adverse Events at 30 Days
Description
Rate of serious adverse events is presented as the percentage of the participants who reported serious adverse events within 30 days after initial treatment. For this study, serious adverse events (SAEs) included death, serious deterioration in health, life threatening injury/illness, hospitalization or prolonged hospitalization, or resulted in medical or surgical intervention.
Time Frame
30 days post-operation
Title
Rate of Procedure/Device Related or Possibly Related Serious Adverse Events at 30 Days
Description
Rate of Procedure/Device related or possibly related serious adverse events is presented as the percentage of the participants who reported Procedure/Device related or possibly related serious adverse events within 30 days after initial treatment.
Time Frame
30 days post-operation
Title
Change in Anterior Vertebral Body Height
Time Frame
Pre-op, Pre-discharge, 3 months, 12 months, 24 months post-operation
Title
Change in Middle Vertebral Body Height
Time Frame
Pre-op, Pre-discharge, 3 months, 12 months, 24 months post-operation
Title
Change in Posterior Vertebral Body Height
Time Frame
Pre-op, Pre-discharge, 3 months, 12 months, 24 months post-operation
Title
Change in Vertebral Body Kyphosis Angle
Description
The vertebral kyphosis angle was defined as the angle formed by lines drawn parallel to the superior and inferior endplates of the treated fractured vertebral body.
Time Frame
Pre-op, Pre-discharge, 3 months, 12 months, 24 months post-operation
Title
Change in Vertebral Body Local Cobb Angle (LCA)
Description
The vertebral body local Cobb angle is a measurement of the 3-level functional unit consisting of the treated fractured vertebral body and the nearest adjacent vertebrae and is defined as the angle formed by lines drawn parallel to the superior endplate of the cranial adjacent vertebral body and the inferior endplate of the adjacent caudal vertebral body.
Time Frame
Pre-op, Pre-discharge, 3 months, 12 months, 24 months post-operation
Title
Change in Global Sagittal Balance.
Description
Change in global sagittal balance as measured by sagittal vertical axis.
Time Frame
Pre-op, Pre-discharge, 3 months, 12 months, 24 months post-operation
Title
VCF-related Health Care Utilization
Description
Health care utilization assessments conducted by monthly phone call to participating patients.
Time Frame
Monthly for 24 months post-op

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria All subjects must meet all of the following criteria to be enrolled into the study: Age > 21 1 to 3 target VCFs meeting the following criteria: Fracture due to diagnosed or presumed underlying primary or secondary osteoporosis All target VCFs are between T5 and L5 All target VCFs to be treated show either: i. Height change: An acute (< 6 month) change in VB height or morphology from a previous x-ray, CT or MRI, with height loss at the anterior, middle or posterior portion of the VB consistent with a worsening of 1 or more grades by the Genant criteria (17), OR ii. Positive MRI or bone scan: VB shows hyperintense signal on STIR sequence MRI or target VB is positive on radionuclide bone scan All VCFs to be treated have fracture age (time from pain onset to evaluation by the Investigator) of 6 months or less Back pain correlating with the location of at least one VCF Treatment of all target VCFs is technically feasible by and clinically appropriate for BOTH vertebroplasty and balloon kyphoplasty. (Team approach only: Both the vertebroplasty and balloon kyphoplasty physician have reviewed radiographic studies and agree to this prior to enrolling the subject in the study.) Pre-treatment back pain by numerical rating scale (NRS) score > 4 (0-10 scale) Pre-treatment Oswestry Disability Index >20 (0 - 100 scale) Subject states availability for all study visits Subject is able to understand the risks and benefits of participating in the study and is willing to provide written informed consent Subject has mental capacity to comply with the protocol requirements for 2-year duration of study Exclusion Criteria Subjects who meet any of the following conditions may not be enrolled into the study: VB morphology or configuration is such that either balloon kyphoplasty OR vertebroplasty is not technically feasible for the targeted VCFs Fracture due to high-energy trauma Suspected OR proven cancer inside index vertebral body. Note that patients with chemotherapy-related osteoporosis may be included. Disabling back pain due to causes other than acute fracture (e.g., sacroiliac fracture, symptomatic degenerative disc disease, lumbar spinal stenosis) Any painful VCF with fracture age > 6 months Any objective evidence of neurologic compromise at baseline Previous balloon kyphoplasty or vertebroplasty for any VCF Spine stabilization beyond balloon kyphoplasty or vertebroplasty required for targeted VCFs Significant clinical comorbidity that may potentially interfere with long-term data collection or follow-up (e.g., dementia, severe comorbid illness) Pre-existing conditions contrary to either balloon kyphoplasty or vertebroplasty, such as: Irreversible coagulopathy or bleeding disorder. Note regarding reversible coagulopathies: Subjects on coumadin or other anticoagulants may participate. Investigators should follow routine practices for perioperative discontinuation and re-initiation of anticoagulants. Allergy to any device materials (e.g., bone cement) for balloon kyphoplasty or vertebroplasty. Note that in subjects with allergy to iodine-based contrast, other non-iodine contrast solutions may be used. Any evidence of VB or systemic infection Pregnant or child-bearing potential
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Reginald Knight, MD
Organizational Affiliation
Orthopedics International
Official's Role
Principal Investigator
Facility Information:
Facility Name
Scottsdale Medical Imaging, Ltd
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85252
Country
United States
Facility Name
Minimally Invasive Surgical Solutions
City
San Jose
State/Province
California
ZIP/Postal Code
95128
Country
United States
Facility Name
Torrance Memorial Medical Center
City
Torrance
State/Province
California
ZIP/Postal Code
90505
Country
United States
Facility Name
Western Slope Study Group
City
Grand Junction
State/Province
Colorado
ZIP/Postal Code
81501
Country
United States
Facility Name
The Center for Spinal Disorders
City
Tampa
State/Province
Florida
ZIP/Postal Code
33637
Country
United States
Facility Name
Radiology Associates of Atlanta
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30309
Country
United States
Facility Name
Ochsner Medical Center
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Facility Name
William Beaumont Hospital
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Facility Name
Saint Luke's Hospital of Kansas City
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
Northwest Research & Educational Institute
City
Billings
State/Province
Montana
ZIP/Postal Code
59101
Country
United States
Facility Name
Renown Regional Medical Center
City
Reno
State/Province
Nevada
ZIP/Postal Code
89502
Country
United States
Facility Name
University Orthopedics
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Atrium Medical Center
City
Franklin
State/Province
Ohio
ZIP/Postal Code
45005
Country
United States
Facility Name
The Toledo Hospital
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43606
Country
United States
Facility Name
Clinical Radiology of Oklahoma
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73003
Country
United States
Facility Name
The Center for Orthopedic and Neurosurgical Care and Research (The Center)
City
Bend
State/Province
Oregon
ZIP/Postal Code
97701
Country
United States
Facility Name
Reading Hospital
City
Reading
State/Province
Pennsylvania
ZIP/Postal Code
19601
Country
United States
Facility Name
The Methodist Hospital Research Institute
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Scott & White Memorial Hospital
City
Temple
State/Province
Texas
ZIP/Postal Code
76508
Country
United States
Facility Name
Intermountain Medical Center
City
Murray
State/Province
Utah
ZIP/Postal Code
84157
Country
United States
Facility Name
Utah Valley Regional Medical Center
City
Provo
State/Province
Utah
ZIP/Postal Code
84604
Country
United States
Facility Name
Carilion Roanoke Memorial Hospital
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24033
Country
United States
Facility Name
St. Mary's Hospital
City
Huntington
State/Province
West Virginia
ZIP/Postal Code
25702
Country
United States
Facility Name
Aurora Burlington Memorial Hospital
City
Burlington
State/Province
Wisconsin
ZIP/Postal Code
53105
Country
United States
Facility Name
Aurora St. Luke's Medical Center
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Royal Victoria Hospital
City
Barrie
State/Province
Ontario
ZIP/Postal Code
L4M6MZ
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

KAVIAR Study - Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures

We'll reach out to this number within 24 hrs